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 Chapter 26 
 The TNO In Vitro Model of the Colon (TIM-2) 
 Koen  Venema 
 Abstract  This contribution describes the development and use of the TNO in vitro 
model of the colon (TIM-2). The unique features of this system are briefl y dis-
cussed, as well as how these contribute to the predictability of this validated in vitro 
model for clinical trials. Several examples are provided of data where experiments 
in TIM-2 yielded similar data as clinical trials. Other examples highlight the use of 
the system to screen dietary components for certain functionality (e.g., increase in 
butyrate production), or determine likely mechanisms of action of dietary substrates 
(e.g., the bifi dogenic nature of dietary carbohydrates). Moreover, examples are pro-
vided of metabolism of dietary compounds such as polyphenols of which the deter-
mination of in vivo metabolism is extremely diffi cult, due to the limited access we 
have to the colon. The system is inoculated with a microbiota originating from 
healthy volunteers (single donor or pooled microbiota) of different age, or from 
people with a disease (e.g., infl ammatory bowel disease). Also, differences between 
the microbiota from lean and obese individuals have been studied. Recent develop-
ments in building hypotheses on the role of the microbiota in health and disease 
have been generated using substrates that were labeled with a stable isotope (i.e.,  13 C), 
that allows tracing the label into microbial biomass and into metabolites produced 
by the gut microbiota. This has signifi cantly advanced our knowledge on the role of 
the activity of the gut microbiota in health and disease and the members of the 
microbiota that are involved in this. 
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26.1  Description of TIM-2 
 This contribution focuses on food-application of TIM-2. Although numerous 
examples are available for pharmaceutical applications as well, these will not be 
exemplifi ed here. 
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26.1.1  History of the Model 
 The  T NO computer-controlled, dynamic in vitro gastro- I ntestinal  M odel of the 
colon (nick-named TIM-2; Fig.  26.1 ) was developed by TNO some 15 years ago 
(Minekus et al.  1999 ). It is based on the TIM-1 system (the TNO in vitro gastro- 
intestinal model of the stomach and small intestine) that is discussed elsewhere in 
this book. 
 Briefl y, the model consists of four interconnected glass compartments, with a 
fl exible membrane inside (Fig.  26.1a ). In between the glass jacket and the membrane 
there is water of body temperature (37 °C for humans, 39 °C for pigs, 41 °C for birds, 
etc.). The temperature is controlled by a temperature sensor (Fig.  26.1j ). By applying 
pressure on the water at regular intervals and in a certain sequence, the fl exible mem-
brane contracts and causes peristaltic waves which mixes the luminal contents and 
moves it through the system. This mixing is better than can be accomplished in a 
fermentor, where phase separation of fl uids and solids occur. The system is kept at a 
pH of 5.8, the pH occurring in the proximal colon, or above by continuous measure-
ment of the pH (Fig.  26.1b ) and secretion of 1M NaOH (Fig.  26.1c ) to neutralize the 
 Fig. 26.1  Schematic fi gure of the TNO in vitro model of the colon (TIM-2). (a) peristaltic com-
partments containing faecal matter; (b) pH electrode; (c) alkali pump; (d) dialysis liquid circuit 
with hollow fi bre membrane; (e) level sensor; (f) N 2 gas inlet; (g) sampling port; (h) gas outlet; (i) 




acids that are produced by the microbiota. To prevent accumulation of microbial 
metabolites, which would lead to the inhibition or death of the microbes in the model 
when they would accumulate, the system is equipped with a dialysate system, 
consisting of a bottle with dialysate, a dialysis membrane running through the model 
and a bottle collecting the spent dialysate (Fig.  26.1d ). This dialysis system is unique, 
and moreover, required to maintain an active microbiota for periods for up to 3 weeks. 
This was the longest the system has been tested. Normally experiments are per-
formed over a period of 1 week (see Sect.  26.2 ). 
 The dialysis system has been tuned to keep physiological concentrations of micro-
bial metabolites in the lumen of the model. For example, short-chain fatty acid (SCFA) 
concentrations are within the physiological range of 80–120 mM (Venema et al. 
 2000 ). The model is equipped with a level sensor to control the volume (Fig.  26.1e ). 
When the volume in the system rises due to addition of the feed or through dialysis, 
this sensor activates the dial-out pump and maintains the volume at a constant level of 
~120 mL. To keep the model anaerobic, it is fl ushed with gaseous nitrogen (Fig.  26.1f ). 
This, plus the activity of the microbiota in the system, keeps the redox-potential at a 
level of ~ −300 mV, which is the value that has been reported to occur in the large 
intestine. Samples can be taken from the lumen through the sampling-port (Fig.  26.1g ) 
or from the spent dialysate (Fig.  26.1d ). This allows for a complete mass-balance to 
be calculated. Gases produced by the microbiota can be sampled too, although nor-
mally this is not done and the gas just escapes from the model through a bubbling-vial 
(Fig.  26.1h ). Frequent sampling over time allows the study of the kinetics of produc-
tion of certain microbial metabolites (e.g., SCFA) on specifi c substrates. It is obvious 
that such sampling is not possible in vivo, and hence TIM-2 allows studying the mode 
of action of certain compounds (foods or drugs) which cannot be studied in detail in 
man, nor in animals. The microbiota in the system is fed through a food syringe 
(Fig.  26.1i ) which contains a simulated ileal effl ux medium (SIEM), which in compo-
sition mimics the components that reach the colon from the terminal ileum through 
the ileal-cecal valve. It consists of some complex carbohydrates, some protein (not all 
protein is digested in the small intestine [SI]), some residual bile (not all bile is 
resorbed in the SI), and some minerals and vitamins [for details see Minekus et al. 
 1999 ; van Nuenen et al.  2003 ; Venema et al.  2000 ]. 
26.1.2  Special Features of the Model 
 Several features in TIM-2 are unique over other models. First of all, the peristaltic 
movements of the fl exible membrane give a better mixing and movement of com-
ponents through the entire model than would be accomplished by stirring (in a 
fermentor) or shaking (on a rocking-platform or otherwise). In TIM-2 there is no 
phase-separation of solids and liquids, which does occur in other systems. Viscous 
‘meals’ or insoluble components can be used without problems in the system. 
Secondly, as eluded to above, the dialysis system is not only unique, but also required 
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to maintain a highly active microbiota with a similar density as that found in the 
human large intestine. In batch incubations or less sophisticated models the micro-
biota is usually inoculated at a much lower density (100-fold or more) and is allowed 
to slowly grow to physiological densities. However, the metabolites produced by 
the microbiota start to inhibit further fermentation at these high densities in these 
systems. Since these metabolites are also taken up by the epithelial cells of the colon 
(colonocytes) in vivo, TIM-2 mimics much better the physiological situation in the 
large intestine. In fact, since all metabolites are collected and can be measured, a(n 
almost) complete mass-balance can be made, which is not possible in vivo, not even 
in animals, although in scientifi c studies usually animal are sacrifi ced to sample as 
much as possible, including blood samples. However, even in animals a mass-
balance is not possible, as e.g., butyrate—one of the SCFA—is used by the colono-
cytes and does not reach the blood circulation. Therefore, TIM-2 allows studying 
(molecular) mechanisms. This is certainly the case if labeled substrates are used, as 
will be discussed in other sections of this chapter. 
 The model is incubated by using a fecal donation from volunteers. This fecal 
donation can be used in two ways: (a) a fecal donation from individual one can be 
introduced into one of the TIM-2 systems, the donation from individual 2 in a second 
unit, and so on. The composition and activity of the microbiota of the individuals can 
then be compared on say one and the same substrate. This has for instance been done 
for lactulose, with ten donors (Venema et al.  2003 ); or (b) the fecal donations of 
several donors are mixed to create a standardized microbiota that can subsequently 
be used for ~100 experiments. This allows comparison of multiple substrates or con-
ditions starting with the same microbiota composition. This pool of fecal donations 
to a certain extent mimics a (small) population. It has been argued by many that 
 mixing different fecal samples may disturb the microbial balance within a single 
fecal sample, but as far as we know, no direct comparison has been done to show this. 
Recently, we have set out to show that by mixing a number of different fecal 
 donations, the functionality of the microbiota is not infl uenced (Aguirre et al.  2014 ). 
That is, the individual microbiotas showed the same functionality as the pool and 
produced very similar amounts and ratios of microbial metabolites (amongst others 
SCFA), despite being different in microbial composition. This underscores our 
hypothesis that there is an enormous functional overlap between microbes in the 
large intestine. This is not entirely surprising, as there are only a limited number of 
biochemical routes (let’s say 5) from e.g., glucose to acetate. Since the microbiota is 
composed of approximately 200 species or more, there has to be enormous func-
tional overlap between these microorganisms. 
 Upon introduction of the microbiota in the system, an adaptation period of 
~16 h is applied, to allow the microbes to adapt to their new environment and the 
feed components. After that the experimental period starts, which normally takes 
72 h (see Sect.  26.2 ). Fecal donations can be obtained from healthy volunteers of 
different age-classes (baby, adults, elderly), people with a disease or disorder 




26.1.3  Stability and Reproducibility of the System 
 Since the model is computer-controlled it is highly reproducible. This has been 
shown e.g., by the clustering of the microbiota after the adaptation period referred 
to in the previous section (Fig.  26.2 ). In this example, the microbiotas originating 
from lean and obese individuals were compared. The fi gure shows that both micro-
biotas clustered separately, but that each t = 0 sample of the lean microbiota clus-
tered very closely together with the other lean samples, and similarly for the obese 
samples. It should be said that the microbiota in this adaptation period undergoes a 
change in composition, as it adapted to the model and feed (Rajilic-Stojanovic et al. 
 2010 ). This is not entirely surprising, as the conditions in the model are different to 
the colon, although we try to simulate them as good as possible. But, the system 
does not contain epithelial cells or immune cells that may infl uence the microbiota 
composition. This will be discussed in more detail later (see Sect.  26.5 ). 
 No matter whether the system is inoculated by a standardized microbiota or a 
microbiota from a single donor, it is highly reproducible. This has been shown in 
numerous studies (Kovatcheva-Datchary et al.  2009 ; Martinez et al.  2012 ; Rose 
et al.  2010 ). This is why experiments in TIM-2 are performed in duplicate. 
 In every project a control with the standard growth medium (SIEM) is performed. 
The other conditions applied in such projects are then compared to the effects 
obtained with the standard medium. This allows correcting for effects that occur 
simply through use of the in vitro model. 
 Fig. 26.2  Phylogentic tree ( left ) and heatmap ( right ) of samples from TIM-2 taken at t = 0 in an 
experiment where a lean and obese microbiota was compared. The lean and obese microbiotas 
cluster separately, although all t = 0 samples of each microbiota (lean or obese) cluster closely 
together 
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26.1.4  Relevance to Human In Vivo Situation 
 The model has been developed and optimized with the use of data from sudden- 
death individuals (Macfarlane et al.  1992 ). The data from these samples with respect 
to microbial metabolites and microbiota composition were used to develop TIM-2. 
 The effect of several food components that have been well-established in vivo 
have been confi rmed in TIM-2. These include the bifi dogenic nature of inulin (van 
Nuenen et al.  2003 ) and galacto-oligosaccharides (GOS) (Maathuis et al.  2012 ), or 
the high production of butyrate out of resistant starches (Rose et al.  2010 ). Due to 
this, the validated system is frequently used to test experimental substrates and is 
thought to be predictive for the in vivo situation. 
 Yet, in some situations the model is even capable of predicting results in the 
proximal colon that cannot be measured in a clinical trial. This has for instance been 
done in experiments using lactulose (Venema et al.  2003 ). Here, fecal donations 
were obtained from volunteers before they ingested lactulose for 10 days, and after. 
Both fecal donations were inoculated independently in TIM-2 and were fed lactu-
lose in the system. The production of the major microbial metabolites, the SCFA, 
was analyzed both in fecal samples as well as in TIM-2 samples. At fi rst surpris-
ingly, the in vivo fecal samples before and after lactulose did not differ in SCFA 
content and ratio, while the samples in TIM-2 showed a marked reduction in butyr-
ate production. However, since lactulose is a disaccharide, it is fermented very 
quickly by the gut microbiota (as also indicated by the accumulation of lactate), and 
this occurs in the proximal colon. We now hypothesize that the SCFA that were 
produced by the microbiota in vivo in the proximal colon were all taken up during 
transit to the distal colon, and that the SCFA present in the excreted fecal samples 
refl ect those produced locally in the distal colon, rather than refl ect the SCFA that 
were produced in the proximal colon. This is highly likely as it has been estimated 
that 95 % of the SCFA produced by the microbiota are absorbed. Therefore, TIM-2 
gave insight in the processes at the site where the fermentation of lactulose hap-
pened—the proximal colon. This is data that could not be inferred from fecal sam-
ples taken from these volunteers. 
26.1.5  Quality in Relation to Other Models 
with the Same Applicability 
 Compared to other in vitro models mimicking the colon, TIM-2 has a number of 
features that are unique (see Sect.  26.1.2 ) and that allow to predict what would 
 happen in a clinical trial. In the previous section the example of lactulose was given. 
To validate these results one would need to sample the proximal colon, which is 
only possible when using a long catheter that is inserted through the nose or throat 
and reaches the proximal colon (Venema  2011 ), or a tube that is stuck up the rectum 
to reach the proximal part of the large intestine. Although this has been done, it is 
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very invasive and it is diffi cult to get ethical approval for testing functionality of 
numerous food components. Nevertheless, it is our belief that the results that were 
found in TIM-2 predict what happens in vivo, even though this could not be con-
fi rmed because the analytes in fecal matter in this case were not representative for 
those produced in the proximal colon, as they had all been absorbed by the colonic 
tissue during transit from proximal to distal colon, which may take anything from 
24 to 72 h. 
 One of the reasons the system can predict what happens in real life so well is the 
presence of the dialysis system. As discussed above, this system prevents the accu-
mulation of microbial metabolites, which normally are also taken up by the gut 
epithelium. In other systems metabolites tend to accumulate. Apart from slowing 
down or stopping further microbial breakdown of the substrates under study 
(Ramasamy et al.  2014 ), both the kinetics and true production of e.g., SCFA are 
inaccurate in these incubations. Since the metabolites are not removed, this allows 
for them to be converted into one another. For example, two molecules of acetate 
can be coupled to form butyrate, while lactate can be converted to propionate or 
butyrate. While this normally occurs to a certain extent in the gut microbiota, and is 
called cross-feeding (Kovatcheva-Datchary et al.  2009 ), in batch incubations this 
happens to a degree that is no longer physiological. 
 Also, the accumulation of the SCFA (in particular) leads to the inhibition of cer-
tain members of the microbiota, certainly if this is accompanied by a drop in 
pH. Because of this, the composition of the microbiota may change and no longer 
refl ect that of the normal gut. It should be said that even in TIM-2 the microbiota 
will change after introduction of the inocula (Rajilic-Stojanovic et al.  2010 ). 
 Due to the fact that the system closely mimics physiological parameters, the 
experiments in TIM-2 usually take 1 week (see Sect.  26.2 ). In contrast, other models 
that mimic the large intestine usually take several weeks due to the need to reach 
steady state. Since multiple units of TIM-2 can be run at the same time (maximally 10), 
comparisons with a control can be made and steady state in TIM-2 is not strictly 
required. For a more extensive review of TIM-2 in comparison to other in vitro mod-
els mimicking the colon, please refer to Venema and van den Abbeele ( 2013 ). 
26.2  General Protocol 
 After introduction of the microbiota into TIM-2 (at ~11 % w/w; 120 mL), the 
microbiota is allowed to adapt to the new situation over a period of 16 h and is fed 
with the standard SIEM medium, composed of complex carbohydrates, protein, 
some ox-bile, Tween 80 and vitamins and minerals (Maathuis et al.  2012 ). A total 
of 60 mL/day of this medium is fed to the microbiota. The medium is provided at a 
speed of 2.5 mL/h, refl ecting the occasional opening and closing of the ileal-cecal 
valve in vivo. 
 After the 16 h adaptation period, there usually is a 2–4 h starvation period to 
allow the microbiota to ferment all the available carbohydrates in the system. 
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After this, the standard medium is replaced by the test carbohydrate. This test 
medium is fed for another 72 h. Just prior to the start of feeding the test medium, 
samples are taken from the lumen and dialysate at t = 0. Subsequently, every 24 h 
samples are taken from both the lumen and dialysate, and after analysis the cumulative 
production of microbial metabolites is calculated. Similarly, samples are taken 
every 24 h from the lumen to study changes in microbiota composition using micro-
array or, nowadays, next generation sequencing technology. 
 Although the above is considered to be a general protocol, every project may 
require the tailor-made adjustment of this protocol. Some experiments may not use 
a carbohydrate test substrate, but e.g. polyphenols (Gao et al.  2006 ; Bordonaro et al. 
 2014 ) or saponins (Kong et al.  2009 ), which requires addition of these compounds 
to the standard medium. 
 Over the past 5 years or so, we have also ran experiments in which we gave a 
single shot of 1 g of uniformly stable-isotope ( 13 C) labeled carbohydrates at t = 0 and 
then followed degradation of these substrates over time. Incorporation of label into 
microbial biomass using Stable Isotope Probing (SIP) (Maathuis et al.  2012 ) and 
into microbial metabolites using NMR and LC-MS (Binsl et al.  2010 ) were used to 
trace the fate of these labeled carbohydrates. 
 By choice no mucin is added to the system. The only commercial source of mucin 
is pig gastric mucin, which has a completely different composition than human colonic 
mucin, and therefore is not a good mimic for human colonic mucin. Therefore, the 
choice was made not to standardly add mucin to TIM-2 fermentations. In cases where 
addition of mucin would be essential, it could be added, although the above should be 
taken into consideration. Similarly, we do not add the insoluble and unfermentable 
cellulose. It is hardly fermentable to the human gut microbiota (Slavin et al.  1981 ), 
and microorganisms capable of using this substrate appear to only be present in fecal 
samples from methane-excretors while this community remained undetectable in 
non-methane-excretors (Robert and Bernalier- Donadille  2003 ). Sometimes however, 
it is used as a negative (non-fermentable) control. 
 Most of the times, the model simulates the proximal colon with a pH of 5.8, 
although sometimes the systems mimics the entire colon and the pH is programmed 
as a gradient over time from 5.8 in the proximal colon, to 6.4 in the transverse colon, 
to 7.0 in the distal colon. The lumen is then considered a plug which transits through 
the different parts of the large intestine. 
26.3  Controls to Test Stability and Performance of the Model 
 TIM-2 is completely computer-controlled. All data with respect to the secretion of 
fl uids (feed, NaOH, dialysate) as well as temperature and pH are monitored and 
stored. Moreover, these values are plotted on a computer-screen, such that the person 
operating the model is immediately aware of how the system is performing. 
Furthermore, the stability and performance of the system is monitored by studying 
these values after the experiment, in addition to monitoring the production of SCFA 
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under standardized conditions. The production of SCFA should essentially be equal 
under identical conditions even if the experiments are performed over a stretch of 
several months. Unfortunately, SCFA cannot be measured online (yet), but the secre-
tion of NaOH (to neutralize the drop in pH caused by the acids) is used as a proxy for 
SCFA production and this has worked very well to monitor the performance of the 
model. When a parameter is out of range, the run is terminated. Usually this happens 
because of a mechanical error in a pump or due to a leak in the system allowing 
 oxygen to diffuse in, which would preclude a complete anaerobic environment. 
 The pH may not drop below 5.8 (the set-point value), but is allowed to rise above 
this value if for instance protein fermentation is expected or occurs. Protein fermen-
tation leads to the production of putrefactive metabolites, amongst others ammonia, 
which raises the pH in the system. Under circumstances of excess protein it may in 
fact raise to a pH near neutrality. 
 The speed of dialysis is important to maintain physiological levels of microbial 
metabolites in the system. If dialysis does not occur (e.g., a pump broke down, or a 
tube got disconnected) this is immediately refl ected in the production of acids 
(with NaOH as the proxy for that) and eventually in the microbiota composition, 
although the latter is only established days to weeks after the experiments, when the 
molecular analyses have been done. 
 Usually the experiments are very reproducible. The standard deviation (or range) 
normally falls within 10 %. This is why it was decided in the early 2000s to only 
perform duplicate experiments, and only repeat an experiment if the duplicates were 
way off. 
26.4  Read-Out of the System and How This Information 
Can Be Used 
 Because of the health benefi t of SCFA (den Besten et al.  2013 ), in particular butyrate 
(Havenaar  2011 ), most of the experiments carried out in the past 15 years focused 
on carbohydrate fermentation and the consequent production of the individual 
SCFA and their ratio. Experiments could screen numerous substrates for optimal 
SCFA production or would advance pre-established hypotheses that certain com-
pounds would lead to the production of increased levels of certain SCFA, such as 
the case for butyrate when starch is fermented. 
 This requires the analysis and calculation for the cumulative production of these 
SCFA over time. Since all metabolites that are produced by the microbiota are 
 collected in the system (from dialysate and lumen) this assessment of total SCFA 
production can be made. 
 Coupled to analyses for SCFA the (change in) composition of the microbiota is 
usually measured, to establish the link between SCFA produced and the micro- 
organisms responsible for this. With the advent of the stable-isotope technology in 
gut microbiology this has become even easier, as there is a direct link between label 
incorporation into metabolites and into microbial biomass (Venema  2011 ). 
26 The TNO In Vitro Model of the Colon (TIM-2)
302
 However, the system has been used for numerous other applications as well. 
For instance, the effect of probiotics upon antibiotic treatment to quickly re-establish 
the microbial balance (Rehman et al.  2012 ), fermentation of polyphenols from tea, 
citrus or chocolate into more simple phenolic compounds, each with their own func-
tionality (Bordonaro et al.  2014 ; Gao et al.  2006 ), or the metabolism of saponins 
from traditional Chinese medicines (Kong et al.  2009 ). No matter what the example, 
the aim has always been to increase the health of the host through the microbiota. 
Recently, the microbiota has also been shown to be involved in obesity (Venema 
 2010 ). This has led to the investigation in TIM-2 of the metabolism of microbiotas 
originating from lean and obese individuals (as yet unpublished). Numerous 
attempts are made to mine the microbiota for functional (healthy) activities 
(Roeselers et al.  2012 ). It is expected that TIM-2 may play a role in deciphering the 
benefi cial microbes and metabolites that play a role in health and disease. 
 Sometimes samples from TIM-2 are incubated with other in vitro models described 
in this book, such as Caco-2 cell cultures (Lamers et al.  2003 ), immune cells 
(van Nuenen et al.  2005 ), or ex vivo pig intestinal tissue. In these cases, the effects of 
the microbial metabolites on parameters studied in these cells are of importance, such 
as barrier function, DNA damage, or induction of satiety hormones (such as GLP-1 or 
PYY). We have recently shown that samples from TIM-2 induce PYY, which is 
involved in appetite regulation, in pig intestinal tissue (Bussolo et al.  2014 ). 
26.5  Advantages, Disadvantages and Limitations 
of the System 
 TNO has 10 units of TIM-2 available, allowing multiple parameters to be tested in 
parallel. In contrast to other multi-compartmental in vitro models, experiments 
are quick (usually three test days or less), yet still physiological and predictive. 
The advantages over other models are the presence of peristaltics and a dialysis 
system, the latter of which allows production of physiological concentrations of 
metabolites, and a highly active microbiota of normal density to be used. Another 
advantage is that a single parameter in the system can be changed, and the effect of 
that single parameter on microbiota activity can be studied. This has been done 
e.g., when studying the effect of different pH’s on fermentation of carbohydrates 
(unpublished). Naturally, in vitro models have their limitations. As with every other 
in vitro model that mimics the colon, TIM-2 does not have epithelial or immune 
cells. However, as discussed in Sect.  26.4 , samples can be incubated with these cells 
for even better predictability. Another limitation is that the model has been developed 
on the basis of literature data of mostly health individuals. Due to this, it is unclear 
exactly which parameters to simulate when simulating patient populations as dis-
cussed in van Nuenen et al. ( 2004 ). Another limitation is that (apart from volume 
and pH) there are no feed-back mechanisms in the system. Therefore, the experi-
ments in such in vitro models will always be at most an indication of what may occur 
in real life, and the results need to be interpreted with care. 
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Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
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